Several years later, the Rosenberg team reported about a patient with metastatic cholangiocarcinoma who received treatment with ex vivo expanded autologous tumor infiltrating lymphocytes (TILs), containing CD4+ T cells specific for a MHC Class II-restricted mutant tumor antigen (neoantigen) (178). Here, CD4 is linked to neoplasm.